Mathias Schmidt
Direktor/Vorstandsmitglied bei JCR PHARMACEUTICALS CO., LTD.
Aktive Positionen von Mathias Schmidt
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| JCR PHARMACEUTICALS CO., LTD. | Direktor/Vorstandsmitglied | 01.06.2020 | - |
| Corporate Officer/Principal | 01.06.2020 | - | |
ArmaGen, Inc.
 ArmaGen, Inc. Hospital/Nursing ManagementHealth Services ArmaGen, Inc. engages in operation of a clinical stage biotechnology company focused on developing revolutionary therapies for severe neurological disorders. Its products include AGT-110-Brain-penetrating biologic tumor necrosis factor inhibitor (TNFI) for Alzheimer's disease, AGT-115-Brain-penetrating erythropoietin (EPO) for stroke, AGT-160-Brain penetrating anti-amyloid antibody (AAA) for Alzheimer's disease and AGT-181-Brain-penetrating iduronidase (IDUA) for Mucopolysaccharidosis (MPS) Type I (Hurler's syndrome). The company was founded by William M. Pardridge and Ruben J. Boado in 2003 and is headquartered in San Diego, CA. | Direktor/Vorstandsmitglied | 01.10.2016 | - |
| Vorstandsvorsitzender | - | - | |
| JCR USA, Inc. | Vorstandsvorsitzender | - | - |
| Präsident | - | - |
Karriereverlauf von Mathias Schmidt
Ausbildung von Mathias Schmidt
| University of Freiburg | Doctorate Degree |
| Universität Stuttgart | Graduate Degree |
Statistik
International
| Deutschland | 3 |
| Vereinigte Staaten | 3 |
| Japan | 2 |
Operativ
| Director/Board Member | 2 |
| Chief Executive Officer | 2 |
| Corporate Officer/Principal | 1 |
Sektoral
| Consumer Services | 3 |
| Health Technology | 2 |
| Health Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| JCR PHARMACEUTICALS CO., LTD. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
ArmaGen, Inc.
ArmaGen, Inc. Hospital/Nursing ManagementHealth Services ArmaGen, Inc. engages in operation of a clinical stage biotechnology company focused on developing revolutionary therapies for severe neurological disorders. Its products include AGT-110-Brain-penetrating biologic tumor necrosis factor inhibitor (TNFI) for Alzheimer's disease, AGT-115-Brain-penetrating erythropoietin (EPO) for stroke, AGT-160-Brain penetrating anti-amyloid antibody (AAA) for Alzheimer's disease and AGT-181-Brain-penetrating iduronidase (IDUA) for Mucopolysaccharidosis (MPS) Type I (Hurler's syndrome). The company was founded by William M. Pardridge and Ruben J. Boado in 2003 and is headquartered in San Diego, CA. | Health Services |
| JCR USA, Inc. |
- Börse
- Insiders
- Mathias Schmidt
- Erfahrung
